ETC-501

ETC-501 is a compound that can cross the blood-brain barrier and is effective when administered orally. It acts as a selective inhibitor of MNK1/MNK2, with an IC50 of 0.033 μM for MNK1 and 0.111 μM for MNK2. This compound inhibits the proliferation of glioblastoma cells, impairs DNA damage repair, delays cell cycle progression, and suppresses ribosome biogenesis. Additionally, ETC-501 enhances Temozolomide-induced cellular senescence, reduces the senescence-associated secretory phenotype, and increases cell sensitivity to Navitoclax. It is applicable for research related to glioblastoma.